Tamoxifen-Resistant MCF7 Breast Cancer Cells (MCF7/TAMR-8)
Payment Options
We accept Visa and MasterCard in our online store.
Worldwide Shipping
We can get your purchases to you wherever you are.
Customer Care
As an Axol customer you have access to our support team and product specialists.
Description
MCF7/TAMR-4 and MCF7/TAMR-8 are tamoxifen-resistant MCF7 breast cancer cell lines. The parental MCF7/S0.5 line was treated with 1 μM tamoxifen for 28 days which killed the majority of the cells. The surviving cells were clonally expanded as sublines in the absence of tamoxifen for 19 passages and were then treated continuously with 1 μM tamoxifen. The resistant cells continued to proliferate and approached a growth rate that was comparable to the parental MCF7/S0.5 line.
Condition of sale: the end user is not permitted to transfer or re-freeze the cells.
Product Specification
| Donor gender | Female |
| Donor age at sampling | 69 yrs |
| Genetic modification | None |
| Size | 1 million cells |
| Growth properties | Adherent |
| Disease information | Malignant adenocarcinoma derived from pleural effusion |
| General notes | Expresses the estrogen receptor (ER); resistant to tamoxifen at 1 μM |
| Shipping conditions | Dry ice |
| Storage conditions | vapour phase nitrogen |
| Usage notes | Culture in DMEM/F12 medium (no phenol red) supplemented with 1% fetal bovine serum + 2.5 mM GlutaMAX + 6 ng/mL insulin. Addition of 1 μM tamoxifen is required to maintain a high level of resistance |
| Condition of sale | The end user is not permitted to transfer or re-freeze the cells |
Technical Resources
References
- Madsen MW, Reiter BE, Lykkesfeldt AE. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line. Molecular and Cellular Endocrinology (1995)
- Beliakoff J, Bagatell R, Paine-Murrieta G et al. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clinical Cancer Research (2003)
- Frankel LB, Lykkesfeldt AE, Hansen JB et al. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Research and Treatment (2007)
- Cutrupi S, Reineri S, Panetto A et al. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene (2012)
- Larsen MS, Yde CW, Christensen IJ et al. Carboplatin treatment of antiestrogen-resistant breast cancer cells. International Journal of Oncology (2012)
- Thrane S, Lykkesfeldt AE, Larsen MS et al. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Research and Treatment (2013)
- Lundqvist J, Yde CW, Lykkesfeldt AE. 1α,25-dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells. Steroids (2014)
- Pedersen AM, Thrane S, Lykkesfeldt AE et al. Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α. International Journal of Oncology (2014)
- Elias D, Vever H, Lænkholm AV et al. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene (2015)
- Thrane S, Pedersen AM, Thomsen MB et al. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene (2015)